Redwood Wealth Management Group LLC Buys 197 Shares of Bristol-Myers Squibb (NYSE:BMY)

Redwood Wealth Management Group LLC increased its holdings in Bristol-Myers Squibb (NYSE:BMY) by 1.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 13,263 shares of the biopharmaceutical company’s stock after buying an additional 197 shares during the period. Redwood Wealth Management Group LLC’s holdings in Bristol-Myers Squibb were worth $749,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Algert Global LLC purchased a new stake in Bristol-Myers Squibb in the 2nd quarter worth approximately $328,000. AMF Tjanstepension AB lifted its stake in Bristol-Myers Squibb by 6.9% in the 3rd quarter. AMF Tjanstepension AB now owns 610,181 shares of the biopharmaceutical company’s stock worth $31,618,000 after purchasing an additional 39,419 shares in the last quarter. Czech National Bank lifted its stake in Bristol-Myers Squibb by 6.9% in the 3rd quarter. Czech National Bank now owns 413,002 shares of the biopharmaceutical company’s stock worth $21,369,000 after purchasing an additional 26,718 shares in the last quarter. GAMMA Investing LLC lifted its stake in Bristol-Myers Squibb by 61.3% in the 3rd quarter. GAMMA Investing LLC now owns 27,386 shares of the biopharmaceutical company’s stock worth $1,417,000 after purchasing an additional 10,410 shares in the last quarter. Finally, SignalPoint Asset Management LLC purchased a new stake in Bristol-Myers Squibb in the 3rd quarter worth approximately $201,000. 76.41% of the stock is owned by institutional investors.

Bristol-Myers Squibb Price Performance

Shares of Bristol-Myers Squibb stock opened at $59.15 on Wednesday. The company’s fifty day simple moving average is $57.63 and its two-hundred day simple moving average is $53.47. The firm has a market cap of $119.97 billion, a PE ratio of -16.48, a price-to-earnings-growth ratio of 2.10 and a beta of 0.45. The company has a quick ratio of 1.09, a current ratio of 1.24 and a debt-to-equity ratio of 2.83. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $61.10.

Bristol-Myers Squibb Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, February 3rd. Investors of record on Friday, January 3rd were paid a dividend of $0.62 per share. The ex-dividend date was Friday, January 3rd. This represents a $2.48 annualized dividend and a yield of 4.19%. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. Bristol-Myers Squibb’s payout ratio is presently -69.08%.

Analyst Ratings Changes

BMY has been the topic of several recent analyst reports. Citigroup increased their target price on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 28th. Cantor Fitzgerald raised their price objective on shares of Bristol-Myers Squibb from $50.00 to $55.00 and gave the company a “neutral” rating in a research report on Tuesday. Morgan Stanley raised their price objective on shares of Bristol-Myers Squibb from $36.00 to $39.00 and gave the company an “underweight” rating in a research report on Tuesday, November 12th. Leerink Partners upgraded shares of Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $55.00 to $73.00 in a research report on Tuesday, November 12th. Finally, Bank of America restated a “neutral” rating and set a $63.00 price objective on shares of Bristol-Myers Squibb in a research report on Tuesday, December 10th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $56.93.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.